New drug targets immune system to tame arthritis
NCT ID NCT07433335
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a new medicine called SR-878 in 27 adults with rheumatoid arthritis. The drug works by blocking a protein that controls immune signals. The main goal is to check safety and find a good dose. Participants will be followed for about 16 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SR-878
What this could lead to
If it works, this could point toward a new treatment for rheumatoid arthritis by calming the immune system.
What could go wrong
This is a very early Phase 1 safety study with only 27 people. It is too small to prove effectiveness, and the drug may cause side effects or fail in later trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
SciRhom clinical trial site
RECRUITINGTbilisi, Georgia
-
SciRhom clinical trial site
RECRUITINGChisinau, Moldova
-
SciRhom clinical trial site
RECRUITINGBucharest, Romania
-
SciRhom clinical trial site
RECRUITINGCluj-Napoca, Romania